We propose the “DRF method” for estimating dosage limits for interstitially administered therapeutic or diagnostic nanomedicines or agents from three characteristic parameters that can be experimentally determined from in vivo data. Please see our resources section for a download of the paper and an Excel DRF calculation.
RCL is proud to announce that we now have available to purchase our own high efficiency iron oxide magnetic nanoparticle specifically formulated for in vivo and in vitro magnetic hyperthermia applications. The product specification is available on our resources page. For more information about the material please contact RCL.
We are pleased to share our latest paper on the “Commentary on the clinical and preclinical dosage limits of interstitially administered magnetic fluids for therapeutic hyperthermia based on current practice and efficacy models” which can be found in our resources section.
RCL is proud to be part of a team of leading European universities, SMEs and hospitals that have recently been awarded a European Commission Horizon 2020 grant to develop a multimodal nanomedicine cancer therapy. Further information can be found on the NoCanTher website.
Excel and MATLAB scripts can now be downloaded from the downloads section. Derivation and measurement protocol is summarised in Appendix 1 of our Journal of Applied Physics Paper “On the reliable measurement of specific absorption rates and intrinsic loss parameters in magnetic hyperthermia materials” available from the resources section.
RCL has been working on a reliable, reproducible and accurate characterisation technique to determine the specific absorption rate (SAR) and intrinsic loss parameter (ILP) without the need for a adiabatic hyperthermia system. The paper highlights the importance for following a standardised method and demonstrates though a representative study of the literature that there exists an under/over estimation of SAR of 5% or more in over 70% of cases. The paper is due for online publication in November 2014. Excel and MATLAB scripts to calculate SAR and ILP will also be available for download from the downloads section.
Multifunctional Nanoparticles for Magnetic Hyperthermia and Indirect Radiation Therapy (RADIOMAG) kicks-off early next month. The Action aims to bring together and to organise the research outcomes from the different participating network members in a practical way to provide clinicians with the necessary input to trial a novel anti-cancer treatment combining magnetic hyperthermia and radiotherapy, also identifying future research objectives upon appraisal of the obtained results. RCL is a partner on the Action and holds a substitute chair on the management committee.
RCL would like to welcome Fang-Yu Lin who will be working at RCL as part of his Doctoral training programme at UCL’s Institute of Biomedical Engineering (IBME) between 2014 and 2018. Fang-Yu will be working on developing thermal and magnetic models as part of the MAGNABLATE project.
RCL has been awarded a second grant from the National Institute for Health Research (NIHR) working in collaboration with UCL and UCH developing hyperthermia technology for magnetic thermoablation in the treatment of early prostate cancer. The project titled MAGNABLATE: MAGnetic NAnoparticle ThermoABLATion – Retention and Maintenance in the prostatE, hopes to enter phase I clinical trials at the beginning of 2015.
RCL has just been awarded a €600,000 grant as part of a €6 million European Commission project named DARTRIX, headed by Professor Kerry Chester from the Cancer Institute at University College London (UCL). RCL’s responsibilities within the project will be to develop cutting edge magnetic hyperthermia technology for the treatment of glioblastoma, an incurable brain cancer. Starting in 2012, the 7th Framework Programme (FP7) will aim to begin human trials late 2014/early 2015.